372 related articles for article (PubMed ID: 16607649)
1. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
Balducci L
Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
[TBL] [Abstract][Full Text] [Related]
2. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
Mundle SD
Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714
[TBL] [Abstract][Full Text] [Related]
4. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
5. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Jabbour E; Kantarjian HM; Koller C; Taher A
Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
7. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
[TBL] [Abstract][Full Text] [Related]
8. Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML
Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
[TBL] [Abstract][Full Text] [Related]
9. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
List AF
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
[TBL] [Abstract][Full Text] [Related]
10. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
[TBL] [Abstract][Full Text] [Related]
11. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support.
Pereira A; Nomdedeu M; Aguilar JL; Belkaid M; Carrió A; Cobo F; Costa D; Rozman M; Sanz C; Nomdedeu B
Am J Hematol; 2011 Mar; 86(3):245-50. PubMed ID: 21328437
[TBL] [Abstract][Full Text] [Related]
12. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
Bowen DT
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
15. Supportive care including growth factors in myelodysplastic syndromes.
Gardin C; Fenaux P
Rev Clin Exp Hematol; 2004 Dec; 8(2):E3. PubMed ID: 16027101
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
17. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
18. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts.
Cermak J; Kacirkova P; Mikulenkova D; Michalova K
Leuk Res; 2009 Nov; 33(11):1469-74. PubMed ID: 19646756
[TBL] [Abstract][Full Text] [Related]
19. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
[TBL] [Abstract][Full Text] [Related]
20. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
